Dechra Pharmaceuticals PLC (LON:DPH) said it “remains confident” about prospects for the current financial year.
Last month in its full-year results the veterinary pharmaceuticals group said it had faced supply chain issues at some of its sites and with contract manufacturers.
In a statement ahead of its annual shareholder meeting on Friday, the FTSE 250 company said it was continuing to resolve these issues but assured that “many of these now been mitigated”.
In preparation for Brexit, Dechra has been changing the ownership of all UK marketing authorisations to the Netherlands, while moving lab testing to Croatia and increasing inventories to avoid potential port delays.
The next scheduled news from Dechra will be its interims in late February.